Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$0.81 USD
-0.01 (-1.70%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $0.81 0.00 (-0.37%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
STRO 0.81 -0.01(-1.70%)
Will STRO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for STRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STRO
Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?
Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?
STRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength?
RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains?
Other News for STRO
Sutro Biopharma (STRO) Partners with FDA to Advance ADC Development | STRO Stock News
Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards ...
Sutro Biopharma enters research collaboration with FDA for ADC standards
Sutro Biopharma Faces NASDAQ Non-Compliance Notice
Sutro, Sarepta, Incyte, Signet, Wix: Trending by Analysts